查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1858091

多形性胶质母细胞瘤治疗市场按治疗类型、药物类别、治疗线、最终用户和分销管道划分 - 全球预测 2025-2032

Glioblastoma Multiforme Treatment Market by Treatment Type, Drug Class, Line Of Therapy, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，多形性胶质母细胞瘤治疗市场将成长至 64.1 亿美元，复合年增长率为 8.38%。

关键市场统计数据
基准年 2024 33.6亿美元
预计年份：2025年 36.5亿美元
预测年份 2032 64.1亿美元
复合年增长率 (%) 8.38%

对多形性胶质母细胞瘤治疗格局进行策略概述，重点在于临床挑战、创新动能和相关人员的需求。

多形性胶质母细胞瘤仍是神经肿瘤学领域最棘手的临床挑战之一，其特征是肿瘤生物学特性具有侵袭性、分子异质性，且难以获得持久的治疗反应。基因组分析、免疫肿瘤学和标靶药物的进步为治疗性介入介入开闢了新的途径，但临床治疗仍需要神经外科、放射肿瘤科、内科肿瘤科和支持治疗团队之间精细的协调。因此，研究、临床治疗和商业化领域的相关人员必须权衡近期治疗需求与对有望提高生存率和生活品质的技术创新进行长期投资之间的关係。

本执行摘要概述了当前的治疗格局，重点介绍了研发和商业化策略的关键转变，并组装了领导者可以采取哪些切实可行的措施来协调产品线、伙伴关係和患者准入计划。本书着重于转化医学的优先事项、营运韧性和以病人为中心的交付模式，帮助决策者应对复杂的监管环境、供应链的波动以及不断变化的医保报销机制，同时始终关注临床疗效和价值创造。

精准医疗的突破、免疫疗法的进步以及多学科整合模式正在推动变革性转变，再形成胶质母细胞瘤的治疗方式。

在精准医疗、免疫疗法和整合式医疗服务的推动下，胶质母细胞瘤的治疗模式正在发生显着变革时期。分子分型和先进的定序正在改变临床治疗思路，使其从「一刀切」的治疗模式转向以生物标记主导的治疗，从而靶向特定的致癌促进要素和肿瘤微环境特征。同时，免疫疗法，例如查核点抑制剂和疫苗平台，正进入后期临床试验和联合治疗策略阶段，促使人们重新评估治疗顺序和患者选择标准。

同时，外科手术技术、立体定位放射放射线手术和放射治疗计划的改进正在增强局部控制方法，并为协同组合方案创造了机会。这些临床进展得到了法律规范的支持，该框架日益认识到需要采用适应性试验设计和真实世界证据来评估效用在罕见和异质性适应症中的疗效。总而言之，这些转变要求临床团队、临床试验设计者和商业领导者跨学科合作，以加速新兴疗法从实验室到临床的转化，同时确保患者公平地获得治疗。

评估美国贸易政策和关税调整对胶质母细胞瘤治疗供应链和创新网络的累积影响

美国贸易政策和关税政策的演变可能会影响神经胶母细胞瘤的治疗生态系统，具体表现在成本结构、关键投入品的供应以及跨境合作的运作流程等方面。活性药物原料药、生技药品製剂或专用设备的关税调整可能会增加製造商和医疗系统的采购成本，这可能会改变其筹资策略，并促使其进行资源配置或供应商多元化。如果再加上试剂和设备交货前置作业时间延长等上游因素的影响，这些压力可能会使临床试验的物流更加复杂，并延迟多国试验的启动或扩展。

除了纯粹的成本影响之外，政策主导的贸易动态可能会改变合作和授权模式。企业可能会加快对区域製造的投资，或寻求其他监管途径以降低关税波动带来的风险。这可能既带来挑战，也带来机会。虽然短期中断可能会增加营运复杂性，但也可能刺激对国内生产能力、区域供应中心和更具韧性的采购路径的投资。供应链透明度和对双重采购的重视对于创新生态系统至关重要，相关人员应积极评估合约条款、库存策略和合作生产协议，以确保研究项目的连续性和患者获得治疗的机会。

细分市场分析揭示了治疗类型、药物类别、治疗线、最终用户和分销管道如何影响临床策略和商业化。

细緻的细分视角揭示了治疗创新如何与临床实践、支付方预期和分销现实相互交织。按治疗类型划分，主要类别包括药物治疗、放射线治疗、支持性治疗和手术。药物治疗包括化疗、基因治疗、免疫治疗和标靶治疗等个人化治疗方法。化疗药物包括Carmustine、合併化疗和Temozolomide等。基因治疗再细分为基因编辑疗法和溶瘤病毒疗法。免疫治疗分为查核点抑制剂和疫苗，标靶治疗包括Bevacizumab和EGFR抑制剂。放射线治疗包括近距离放射治疗、体外放射线治疗和放射线手术。支持性治疗包括抗癫痫药物和皮质类固醇。手术介入的范围从切片检查到开颅手术。

依药物类别划分，烷化剂（如Carmustine和PembrolizumabTemozolomide）仍然是基石，而免疫查核点抑制剂（如Nivolumab和帕博利珠单抗）、单株抗体（如贝伐珠单抗）、溶瘤病毒疗法（如西替莫基因）以及包括树突状细胞疫苗和胜肽疫苗在内的疫苗平台完善了治疗方案。治疗线细分区分第一线、二线和三线疗法，每种疗法都有不同的临床终点、耐受性优先考虑因素和证据阈值。最终用户涵盖家庭医疗保健、一线、研究机构和专科诊所，分销管道涵盖医院药房、线上药房和零售药房。这些细分结合起来，为评估临床效用、研发风险和商业性路径提供了一个结构化的框架，使相关人员能够设定符合实际医疗服务模式的投资目标、试验设计和上市策略。

亚太、欧洲、中东和非洲的区域动态正在影响医疗服务取得、监管重点和医疗服务模式。

区域差异对胶质母细胞瘤疗法的研发、核准和应用有着至关重要的影响。在美洲，先进的临床试验基础设施、专业的癌症中心和完善的医保报销机制共同促进了新型疗法的快速应用，但支付方的监管和预算考虑在商业化规划中仍然发挥着重要作用。在欧洲、中东和非洲，不同的监管路径、神经外科专科中心资源的差异以及卫生技术评估时间线的显着差异，共同造就了复杂的市场环境，并影响药物的实施和定价策略。亚太地区的特点是临床研究能力的快速发展、政府对本土生产的大力支持、精准肿瘤学能力的持续投入。这些因素共同为区域伙伴关係和在地化的打入市场策略创造了蓬勃发展的机会。

这些地区的监管细则、报销方式和医疗服务模式差异显着，因此製造商和医疗系统需要相应地调整其临床证据产生和准入计划。跨区域合作、技术转移安排和量身定制的患者支援可以弥合医疗服务方面的差距。透过将临床开发计划与区域监管要求和医疗服务基础设施相协调，相关人员可以在控制营运和商业风险的同时，提高患者及时获得治疗的可能性。

竞争格局：重点在于研发重点、临床管线差异化、合作以及生产製造优先事项，这些因素共同塑造了胶质母细胞瘤治疗药物的研发过程。

胶质母细胞瘤领域的企业策略日益依赖差异化的研发组合、有针对性的合作以及规划好的生产布局。主要企业正优先进行强有力的转化项目，以检验生物标记、优化组合方案并产生机制证据，从而支持监管申报和与支付方的沟通。临床研发管线涵盖了多种后期免疫疗法、针对可靶向突变的标靶药物以及旨在提高中枢神经系统渗透性的创新递送技术。为了保持竞争优势，各公司正投资于适应性试验设计、篮子试验和真实世界证据的生成，以加速适应症拓展并为医保报销申请提供依据。

生物製药公司、学术中心和受託製造厂商之间的伙伴关係正变得日益战略化，许多公司寻求共同开发安排，以共用临床风险并获得细胞和基因疗法的专业生产资源。需要考虑的因素包括地域容量、品质系统和供应链冗余，尤其是在复杂生物製药和病毒载体的生产方面。在商业性，早期与临床医生、支付方和患者权益组织合作的公司在简化产品推广方面具有优势，而投资于数据基础设施和结果指标的公司则在向支付方和整个医疗保健系统证明其价值方面具有优势。

为行业领导者提供切实可行的建议，以加速转化研究、优化临床路径并增强以患者为中心的医疗服务可及性。

行业领导者应优先采取一系列切实可行的措施，以加速转化医学进程并改善患者可及性。首先，研发投资应集中于高价值的转化路径，以检验生物标记和联合治疗策略，从而提高临床成功率并促进监管审批。其次，应采用灵活的试验架构和可操作的终点指标，兼顾科学严谨性和可行性，从而提高患者招募效率，并在异质人群中清晰地检测到讯号。第三，应加强临床营运、法规事务、生产製造和商业团队之间的跨职能协作，确保研发项目从早期阶段就考虑到医保报销和供应链的实际情况。

同时，领导者应加强以患者为中心的医疗服务获取策略，投资于中心辐射式医疗模式、用于监测和依从性的数位化健康工具，以及旨在减少治疗启动和持续性障碍的客製化支持计画。风险缓解措施，例如双重采购、紧急库存计划和合约保护，可以确保临床实验和商业供应的连续性。最后，与学术中心、专科诊所和第三方製造商建立策略伙伴关係，可以加速能力建设，同时分散专案风险，使机构能够快速回应临床机会和政策变化。

调查方法概述了胶质母细胞瘤研究的主要和次要研究资料收集、专家参与以及分析框架。

本分析的方法论结合了专家临床医生、临床实验研究人员、製造商和患者权益倡导者的定性访谈，以及整合同行评审文献、临床试验註册资讯和监管指南的结构化二手研究。专家访谈提供了关于临床实践差异、临床试验设计权衡和真实世界治疗路径的背景信息，而二手信息则用于对治疗机制、安全性特征和比较疗法的疗效进行三角验证。分析架构包括跨领域分析、产品线优先排序矩阵和情境规划，以评估不同政策和供应链条件下的营运和商业性影响。

这种方法兼顾了深度和广度。初步调查确保了基于当前实践的洞见，并捕捉了新兴的临床趋势；而係统的二次综合分析则提供了可复製的依证。在适当情况下，分析会纳入对采购和监管环境的结构化敏感度分析，重点相关人员的应对措施和策略性紧急计画。

总结性综述将临床现实、政策影响和创新机会联繫起来，以指导下一步的研究、护理和商业性成功。

总之，胶质母细胞瘤治疗领域正处于快速科学进展与持续临床复杂性的交会点。分子诊断、免疫疗法合併治疗和局部控制技术的进步为改善患者预后提供了实际的机会。然而，包括贸易因素和区域监管差异在内的政策和供应链动态，增加了营运的复杂性，必须积极主动地加以管理，以保障临床试验的连续性和患者的治疗机会。

展望未来，将转化优先事项与切实可行的营运计划相结合的相关人员，将更有利于把创新转化为有意义的治疗方案。跨部门合作、投资于具有韧性的供应链以及与支付方和监管机构持续对话，并专注于以患者为中心的治疗结果和公平的医疗服务获取，将加速高价值治疗方法的推广应用。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将肿瘤治疗与个人化CAR-T细胞疗法结合，以改善胶质母细胞瘤患者的预后
  • 标靶EGFRvIII和PD-1路径双特异性抗体在胶质母细胞瘤免疫治疗的出现
  • 开发一种对流增强型递送系统，用于精准地将药物输送穿过血脑障壁
  • 利用液态切片技术即时监测胶质母细胞瘤的治疗反应和抗药性
  • 增加对溶瘤病毒疗法的投资，该疗法旨在选择性地靶向胶质母细胞瘤干细胞群。
  • 肿瘤微环境调变器的临床进展，可克服胶质母细胞瘤治疗中的免疫抑制微环境

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 多形性胶质母细胞瘤治疗市场依治疗类型划分

  • 药物治疗
    • 化疗
      • Carmustine
      • 合併化疗
      • Temozolomide
    • 基因治疗
      • 基因编辑
      • 溶瘤病毒疗法
    • 免疫疗法
      • 查核点抑制剂
      • 疫苗
    • 标靶治疗
      • Bevacizumab
      • EGFR抑制剂
  • 放射线治疗
    • 近距离放射治疗
    • 放射治疗
    • 放射线手术
  • 支持性护理
    • 抗癫痫药物
    • 皮质类固醇
  • 外科手术
    • 切片检查程序
    • 开颅手术

9. 多形性胶质母细胞瘤治疗市场（依药物类别划分）

  • 烷化剂
    • Carmustine
    • Temozolomide
  • 查核点抑制剂
    • Nivolumab
    • Pembrolizumab
  • 单株抗体
    • Bevacizumab
  • 溶瘤病毒疗法
    • 希莫根·塞拉德诺瓦克
  • 疫苗疗法
    • 树突细胞疫苗
    • 胜肽疫苗

10. 多形性胶质母细胞瘤治疗市场（依治疗线划分）

  • 一线
  • 第二行
  • 三线

第十一章 多形性胶质母细胞瘤治疗市场（依最终用户划分）

  • 家庭医疗保健
  • 医院
  • 研究所
  • 专科诊所

12. 多形性胶质母细胞瘤治疗市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 多形性胶质母细胞瘤治疗市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 多形性胶质母细胞瘤治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 多形性胶质母细胞瘤治疗市场（依国家划分）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche Ltd
    • Merck & Co., Inc.
    • Novocure Ltd.
    • Teva Pharmaceutical Industries Limited
    • Viatris Inc.
    • Sandoz International GmbH
    • Dr. Reddy's Laboratories Limited
    • Accord Healthcare Limited
    • Zydus Lifesciences Limited
    • Sun Pharmaceutical Industries Limited
Product Code: MRR-C002B1C996F6

The Glioblastoma Multiforme Treatment Market is projected to grow by USD 6.41 billion at a CAGR of 8.38% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.36 billion
Estimated Year [2025] USD 3.65 billion
Forecast Year [2032] USD 6.41 billion
CAGR (%) 8.38%

Strategic overview of glioblastoma multiforme treatment landscape highlighting clinical challenges, innovation momentum, and stakeholder imperatives

Glioblastoma multiforme remains one of the most formidable clinical challenges in neuro-oncology, defined by aggressive tumor biology, heterogeneity at the molecular level, and entrenched barriers to durable treatment response. Advances in genomic profiling, immuno-oncology, and targeted agents have created new avenues for therapeutic intervention, yet the clinical pathway still requires nuanced coordination among neurosurgery, radiation oncology, medical oncology, and supportive care teams. As a result, stakeholders across research, clinical care, and commercialization must balance near-term care delivery needs with long-term investments in innovation that promise improved survival and quality of life.

This executive summary synthesizes the current therapeutic landscape, highlights pivotal shifts in R&D and commercial strategy, and frames pragmatic actions that leaders can take to align pipelines, partnerships, and patient access programs. By concentrating on translational priorities, operational resilience, and patient-centric delivery models, the document prepares decision-makers to navigate regulatory complexity, supply chain volatility, and evolving reimbursement environments while maintaining focus on clinical outcomes and value creation.

Transformative shifts reshaping glioblastoma care driven by precision medicine breakthroughs, immunotherapy advances, and integrated multidisciplinary models

The glioblastoma treatment landscape is undergoing a period of substantive transformation driven by precision medicine, immunotherapy, and integrated care delivery. Molecular subtyping and advanced sequencing have shifted clinical thinking away from one-size-fits-all approaches toward biomarker-driven interventions that target specific oncogenic drivers or tumor microenvironment characteristics. Concurrently, immunotherapies, including checkpoint inhibitors and vaccine platforms, have moved into late-stage clinical testing and combination strategies, prompting a re-evaluation of therapeutic sequencing and patient selection criteria.

In parallel, improvements in surgical techniques, stereotactic radiosurgery, and radiotherapy planning have strengthened local control approaches and created opportunities for synergistic multimodal regimens. These clinical advances are supported by evolving regulatory frameworks that increasingly recognize the need for adaptive trial designs and real-world evidence to assess benefit in rare and heterogeneous indications. Taken together, these shifts demand that clinical teams, trial designers, and commercial leaders coordinate across disciplines to accelerate translation from bench to bedside while ensuring equitable patient access to emerging therapies.

Assessing the cumulative impact of United States trade policy and tariff adjustments on glioblastoma treatment supply chains and innovation networks

Evolving United States trade policy and tariff considerations can influence the glioblastoma treatment ecosystem by affecting the cost structure, availability of critical inputs, and the operational cadence of cross-border collaborations. Tariff adjustments on active pharmaceutical ingredients, biologics components, or specialized equipment have the potential to raise procurement costs for manufacturers and health systems, which may in turn shift sourcing strategies and prompt reshoring or supplier diversification. When combined with upstream effects such as increased lead times for reagents and devices, these pressures can complicate clinical trial logistics and slow the initiation or expansion of multinational studies.

Beyond pure cost impacts, policy-driven trade dynamics can alter patterns of partnership and licensing. Companies may accelerate in-region manufacturing investments or pursue alternative regulatory routes to mitigate exposure to tariff volatility. This can create both headwinds and opportunities: while near-term disruptions may increase operational complexity, they can also incentivize investments in domestic production capacity, regional supply hubs, and more resilient procurement pathways. For innovation ecosystems, an increased emphasis on supply chain transparency and dual sourcing will be essential, and stakeholders should proactively assess contract terms, inventory strategies, and collaborative manufacturing agreements to preserve continuity for research programs and patient treatment access.

Segmentation analysis revealing how treatment types, drug classes, therapy lines, end users, and distribution channels jointly inform clinical strategy and commercialization

A nuanced segmentation lens reveals where therapeutic innovation intersects with clinical practice, payer expectations, and distribution realities. When examined by treatment type, key categories include Drug Therapy, Radiotherapy, Supportive Care, and Surgical. Within Drug Therapy there are discrete modalities such as Chemotherapy, Gene Therapy, Immunotherapy, and Targeted Therapy; Chemotherapy itself encompasses agents like Carmustine, Combination Chemotherapy, and Temozolomide, while Gene Therapy subdivides into Gene Editing and Oncolytic Virus Therapy. Immunotherapy splits into Checkpoint Inhibitors and Vaccines, and Targeted Therapy includes agents such as Bevacizumab and EGFR Inhibitors. Radiotherapy covers Brachytherapy, External Beam Radiotherapy, and Radiosurgery, Supportive Care addresses Antiepileptic Drugs and Corticosteroids, and Surgical interventions range from Biopsy Procedures to Craniotomy.

Viewed through the prism of drug class, alkylating agents such as Carmustine and Temozolomide remain foundational, while checkpoint inhibitors represented by agents like Nivolumab and Pembrolizumab, monoclonal antibodies exemplified by Bevacizumab, oncolytic virus therapies such as sitimogene ceradenovac, and vaccine platforms including dendritic cell vaccines and peptide vaccines round out the therapeutic palette. Line-of-therapy segmentation differentiates First Line, Second Line, and Third Line approaches, each with distinct clinical endpoints, tolerability priorities, and evidence thresholds. End users span Home Healthcare, Hospitals, Research Institutes, and Specialty Clinics, and distribution channels move through Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. Together, these segmentation dimensions provide a structured framework for assessing clinical utility, development risk, and commercial pathways, enabling stakeholders to target investments, design trials, and configure go-to-market strategies that map to real-world care delivery patterns.

Regional dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific that shape access, regulatory priorities, and care delivery models

Regional variation exerts a decisive influence on how glioblastoma therapies are developed, approved, and delivered. In the Americas, a combination of advanced clinical trial infrastructure, centralized cancer centers, and established reimbursement mechanisms supports rapid adoption of novel therapeutics, though payer scrutiny and budget impact considerations remain influential in commercialization planning. Europe, the Middle East & Africa presents a heterogeneous picture with diverse regulatory pathways, variable access to specialized neurosurgical capabilities, and significant differences in health technology assessment timelines that affect uptake and pricing strategies. In Asia-Pacific, the landscape is characterized by fast-expanding clinical research capacity, strong government interest in domestic manufacturing, and growing investment in precision oncology capabilities that together create dynamic opportunities for regional partnerships and localized market entry strategies.

Regulatory nuance, reimbursement modalities, and healthcare delivery models differ materially across these regions, so manufacturers and health systems must calibrate clinical evidence generation and access programs accordingly. Cross-regional collaborations, technology transfer arrangements, and tailored patient support mechanisms can bridge gaps in care delivery. By aligning clinical development plans with regional regulatory expectations and delivery infrastructures, stakeholders can improve the likelihood of timely patient access while managing operational and commercial risk.

Competitive landscape spotlighting R&D focus, clinical pipeline differentiation, partnerships, and manufacturing priorities shaping glioblastoma therapy development

Company strategies in glioblastoma are increasingly defined by differentiated R&D portfolios, targeted partnerships, and deliberate manufacturing positioning. Leading organizations prioritize robust translational programs to validate biomarkers, optimize combination regimens, and generate mechanistic evidence that supports regulatory submissions and payer dialogue. Clinical pipelines show a mix of late-stage combination immunotherapies, targeted agents addressing actionable mutations, and innovative delivery technologies aimed at improving central nervous system penetration. To sustain competitive advantage, companies are investing in adaptive trial designs, basket studies, and real-world evidence generation that can accelerate label expansions and inform reimbursement dossiers.

Partnerships between biopharma, academic centers, and contract manufacturing organizations have grown more strategic, with many companies seeking co-development arrangements to share clinical risk and access specialized manufacturing for cell and gene therapies. Manufacturing considerations-particularly for complex biologics and viral vectors-drive decisions about geographic capacity, quality systems, and supply chain redundancy. Commercially, companies that integrate early engagement with clinicians, payers, and patient advocacy groups position themselves to streamline uptake, while those that invest in data infrastructure and outcomes measurement are better equipped to demonstrate value across payers and health systems.

Actionable recommendations for industry leaders to accelerate translational research, optimize clinical pathways, and strengthen patient-centric access

Industry leaders should prioritize a set of pragmatic actions that accelerate translational progress and improve patient access. First, align R&D investments to high-value translational pathways that validate biomarkers and combination strategies, thereby improving the probability of clinical success and facilitating regulatory engagement. Second, adopt flexible trial architectures and pragmatic endpoints that balance scientific rigor with operational feasibility, enabling more efficient patient enrollment and clearer signal detection across heterogeneous populations. Third, strengthen cross-functional collaborations among clinical operations, regulatory affairs, manufacturing, and commercial teams to ensure that development programs are informed by reimbursement and supply chain realities from inception.

In parallel, leaders should reinforce patient-centric access strategies by investing in hub-and-spoke care models, digital health tools for monitoring and adherence, and tailored support programs that reduce barriers to therapy initiation and continuation. Risk mitigation measures such as dual sourcing, contingency inventory planning, and contractual protections can preserve continuity for trials and commercial supply. Finally, strategic partnerships with academic centers, specialty clinics, and third-party manufacturers can accelerate capability building while distributing program risk, enabling organizations to respond quickly to clinical opportunities and policy shifts.

Research methodology outlining primary and secondary data collection, expert engagement, and analytical frameworks for glioblastoma insights

The methodology underpinning this analysis combines primary qualitative engagement with expert clinicians, trial investigators, manufacturers, and patient advocates alongside structured secondary research synthesizing peer-reviewed literature, clinical trial registries, and regulatory guidance. Expert interviews provided contextual nuance on clinical practice variation, trial design trade-offs, and real-world treatment pathways, while secondary sources were used to triangulate evidence on therapeutic mechanisms, safety profiles, and comparative modality performance. Analytical frameworks included cross-segmentation mapping, pipeline prioritization matrices, and scenario planning to evaluate operational and commercial implications under differing policy and supply chain conditions.

This approach balances depth and breadth: primary engagement ensures current, practice-based insights and captures emerging clinical sentiment, while systematic secondary synthesis provides a reproducible evidence base. Where appropriate, the analysis incorporates structured sensitivity around procurement and regulatory scenarios to highlight resilience levers and strategic contingencies that stakeholders can deploy in response to evolving external conditions.

Concluding synthesis that connects clinical realities, policy influences, and innovation opportunities to guide research, care, and commercial next steps

In conclusion, the glioblastoma treatment arena sits at the intersection of rapid scientific progress and persistent clinical complexity. Molecular diagnostics, immunotherapy combinations, and advances in local control techniques offer tangible opportunities to improve patient outcomes, yet translating these advances into consistent clinical benefit requires integrated strategy across development, manufacturing, and access functions. Policy and supply chain dynamics, including trade considerations and regional regulatory variability, add layers of operational complexity that must be proactively managed to protect trial continuity and patient access.

Moving forward, stakeholders who synchronize translational priorities with pragmatic operational plans will be best positioned to convert innovation into meaningful therapeutic options. Cross-sector collaboration, investments in resilient supply chains, and sustained dialogue with payers and regulatory authorities will accelerate adoption of high-value therapies while maintaining the focus on patient-centered outcomes and equitable access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of tumor-treating fields with personalized CAR T-cell therapies to improve glioblastoma patient outcomes
  • 5.2. Emergence of bispecific antibodies targeting EGFRvIII and PD-1 pathways in glioblastoma immunotherapy
  • 5.3. Development of convection-enhanced delivery systems for precision drug transport across the blood brain barrier
  • 5.4. Adoption of liquid biopsy techniques for real-time monitoring of glioblastoma treatment response and resistance
  • 5.5. Rising investment in oncolytic virus therapies engineered to selectively target glioblastoma stem cell populations
  • 5.6. Clinical advancement of tumor microenvironment modulators to overcome immunosuppressive niches in glioblastoma treatment

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Glioblastoma Multiforme Treatment Market, by Treatment Type

  • 8.1. Drug Therapy
    • 8.1.1. Chemotherapy
      • 8.1.1.1. Carmustine
      • 8.1.1.2. Combination Chemotherapy
      • 8.1.1.3. Temozolomide
    • 8.1.2. Gene Therapy
      • 8.1.2.1. Gene Editing
      • 8.1.2.2. Oncolytic Virus Therapy
    • 8.1.3. Immunotherapy
      • 8.1.3.1. Checkpoint Inhibitors
      • 8.1.3.2. Vaccines
    • 8.1.4. Targeted Therapy
      • 8.1.4.1. Bevacizumab
      • 8.1.4.2. EGFR Inhibitors
  • 8.2. Radiotherapy
    • 8.2.1. Brachytherapy
    • 8.2.2. External Beam Radiotherapy
    • 8.2.3. Radiosurgery
  • 8.3. Supportive Care
    • 8.3.1. Antiepileptic Drugs
    • 8.3.2. Corticosteroids
  • 8.4. Surgical
    • 8.4.1. Biopsy Procedures
    • 8.4.2. Craniotomy

9. Glioblastoma Multiforme Treatment Market, by Drug Class

  • 9.1. Alkylating Agents
    • 9.1.1. Carmustine
    • 9.1.2. Temozolomide
  • 9.2. Checkpoint Inhibitors
    • 9.2.1. Nivolumab
    • 9.2.2. Pembrolizumab
  • 9.3. Monoclonal Antibodies
    • 9.3.1. Bevacizumab
  • 9.4. Oncolytic Virus Therapies
    • 9.4.1. Sitimogene Ceradenovac
  • 9.5. Vaccine Therapies
    • 9.5.1. Dendritic Cell Vaccines
    • 9.5.2. Peptide Vaccines

10. Glioblastoma Multiforme Treatment Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Second Line
  • 10.3. Third Line

11. Glioblastoma Multiforme Treatment Market, by End User

  • 11.1. Home Healthcare
  • 11.2. Hospitals
  • 11.3. Research Institutes
  • 11.4. Specialty Clinics

12. Glioblastoma Multiforme Treatment Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Glioblastoma Multiforme Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Glioblastoma Multiforme Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Glioblastoma Multiforme Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Merck & Co., Inc.
    • 16.3.3. Novocure Ltd.
    • 16.3.4. Teva Pharmaceutical Industries Limited
    • 16.3.5. Viatris Inc.
    • 16.3.6. Sandoz International GmbH
    • 16.3.7. Dr. Reddy's Laboratories Limited
    • 16.3.8. Accord Healthcare Limited
    • 16.3.9. Zydus Lifesciences Limited
    • 16.3.10. Sun Pharmaceutical Industries Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINATION CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIOSURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BIOPSY PROCEDURES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CRANIOTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CARMUSTINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TEMOZOLOMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY ONCOLYTIC VIRUS THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SITIMOGENE CERADENOVAC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SITIMOGENE CERADENOVAC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SITIMOGENE CERADENOVAC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SITIMOGENE CERADENOVAC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SITIMOGENE CERADENOVAC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SITIMOGENE CERADENOVAC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY VACCINE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION